Tirzepatide, marketed under the brand name Mounjaro, is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist that was authorized for use in type 2 diabetes in May 2022 [1]. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.